Skip to main content

#155106

Anti-GalNAc-T3 [UH5]

Cat. #155106

Anti-GalNAc-T3 [UH5]

Cat. #: 155106

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: GalNAc-T3/GALNT3

Class: Monoclonal

Application: ELISA ; IHC ; IF ; IP

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: University of Copenhagen

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-GalNAc-T3 [UH5]
  • Alternate name: UH5, 2D1
  • Research fields: Biochemistry;Cancer;Cell biology
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; IHC ; IF ; IP
  • Description: GalNAc-T3 is one of many polypeptide GalNAc-transferases that attach GalNAc to proteins forming the GalNAc??1-O-Ser/Thr linkage for GalNAc-type O-glycosylation. The GalNAc-transferase isoforms have considerably overlapping functions as well as unique distinct functions. GalNAc-T3 is differentially expressed in normal tissues e.g. pancreas, kidney, reproductive and gastrointestinal tracts. Genetic deficiency in GalNAc-T3 results in familial tumoral calcinosis and hyperostosis hyperphosphatemia syndrome due to lack of O-glycosylation of FGF23, which is a key regulator of serum phosphate homeostasis. GalNAc-T3 has also been implicated in spermatogenesis and carcinogenesis. O-glycans are important biomarkers in cancer. The truncated O-glycans comprising Tn formed by the GalNAc transferases and T formed by further elongation by the core1 synthase (C1GalT1) are widely recognized as pancarcinoma antigens. They are masked by sialic acid or further elongation or branching in normal cells. Validation: 1. Positive reaction (IC/IF) in cells expressing GalNAc-T3 using close isoforms as negative controls e.g. GalNAc-T6. 2. Selective IP of active GalNAc-T3 from total cell extracts. 3. Distinct perinuclear staining in cell lines (ICC/IF) and tissues (IHC, IF) suggestive of Golgi localization. 4. loss of staining (IC/IF) following KO of GalNAc-T3.
  • Immunogen: Catalytically active secreted GalNAc-T3 produced in insect cells. Recombinant protein containing aa. 52-633 (Uniprot isoform-1)
  • Immunogen uniprot id: Q14435
  • Isotype: IgG1

Target Details

  • Target: GalNAc-T3/GALNT3
  • Target background: GalNAc-T3 is one of many polypeptide GalNAc-transferases that attach GalNAc to proteins forming the GalNAc1-O-Ser/Thr linkage for GalNAc-type O-glycosylation. The GalNAc-transferase isoforms have considerably overlapping functions as well as unique distinct functions. GalNAc-T3 is differentially expressed in normal tissues e.g. pancreas, kidney, reproductive and gastrointestinal tracts. Genetic deficiency in GalNAc-T3 results in familial tumoral calcinosis and hyperostosis hyperphosphatemia syndrome due to lack of O-glycosylation of FGF23, which is a key regulator of serum phosphate homeostasis. GalNAc-T3 has also been implicated in spermatogenesis and carcinogenesis. O-glycans are important biomarkers in cancer. The truncated O-glycans comprising Tn formed by the GalNAc transferases and T formed by further elongation by the core1 synthase (C1GalT1) are widely recognized as pancarcinoma antigens. They are masked by sialic acid or further elongation or branching in normal cells. Validation: 1. Positive reaction (IC/IF) in cells expressing GalNAc-T3 using close isoforms as negative controls e.g. GalNAc-T6. 2. Selective IP of active GalNAc-T3 from total cell extracts. 3. Distinct perinuclear staining in cell lines (ICC/IF) and tissues (IHC, IF) suggestive of Golgi localization. 4. loss of staining (IC/IF) following KO of GalNAc-T3.

Applications

  • Application: ELISA ; IHC ; IF ; IP

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Dry ice

References

  • A validated collection of mouse monoclonal antibodies to human glycosyltransferases functioning in mucin-type O-glycosylation.
  • Exploring Regulation of Protein O-Glycosylation in Isogenic Human HEK293 Cells by Differential O-Glycoproteomics.
  • Expression of the O-Glycosylation Enzyme GalNAc-T3 in the Equatorial Segment Correlates with the Quality of Spermatozoa.
  • Deconstruction of O-glycosylation--GalNAc-T isoforms direct distinct subsets of the O-glycoproteome.
  • Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family.
  • Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation.
  • Mandel et al. 1999. Glycobiology. 9(1):43-52. PMID: 9884405.
  • cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-galactosamine. Polypeptide N-acetylgalactosaminyltransferase, GalNAc-t3.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.